Cardio Diagnostics to introduce coronary heart disease test in India

Cardio Diagnostics has signed an agreement with Aimil and Dr Lal PathLabs to bring its PrecisionCHD blood test to India, marking the company's first expansion outside the US. Integration into Dr Lal PathLabs' network of more than 290 clinical laboratories is underway, with a broader commercial rollout anticipated in 2026.

Cardio Diagnostics has signed an agreement with Aimil and Dr Lal PathLabs to introduce its PrecisionCHD coronary heart disease test in India. This marks the company's first expansion beyond the United States. The partners say the move responds to rising rates of coronary heart disease in India. The test is reported to use genetic and epigenetic analysis alongside AI to detect heart disease at a molecular level. Key facts: - Cardio Diagnostics signed the agreement with AI-driven business Aimil and healthcare test provider Dr Lal PathLabs to introduce PrecisionCHD in India. - The initial phase involves integrating the test into Dr Lal PathLabs' network of more than 290 clinical laboratories and over 300 MD pathologists, with attention to Indian regulatory and clinical protocols. - The company reports that PrecisionCHD can detect both obstructive and non-obstructive coronary heart disease, including MINOCA and INOCA, and supporting data were presented at the American Heart Association Scientific Sessions. - Partners plan to accelerate a commercial rollout across India, which is anticipated in 2026. Summary: Officials announced the partnership and said integration into Dr Lal PathLabs' laboratory network is underway. The test is reported to identify obstructive and non-obstructive coronary heart disease at a molecular level. A wider commercial rollout across India is expected in 2026.